BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

526 related articles for article (PubMed ID: 3084167)

  • 21. Five years' experience of intrauterine contraception with the Nova-T and the Copper-T-200.
    Luukkainen T; Allonen H; Nielsen NC; Nygren KG; Pyörälä T
    Am J Obstet Gynecol; 1983 Dec; 147(8):885-92. PubMed ID: 6650625
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intrauterine devices. The optimal long-term contraceptive method?
    Fortney JA; Feldblum PJ; Raymond EG
    J Reprod Med; 1999 Mar; 44(3):269-74. PubMed ID: 10202746
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Health during prolonged use of levonorgestrel 20 micrograms/d and the copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. International Committee for Contraception Research (ICCR).
    Sivin I; Stern J
    Fertil Steril; 1994 Jan; 61(1):70-7. PubMed ID: 8293847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early chorionic activity in women bearing inert IUD, copper IUD and levonorgestrel-releasing IUD.
    Videla-Rivero L; Etchepareborda JJ; Kesseru E
    Contraception; 1987 Aug; 36(2):217-26. PubMed ID: 3123135
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ovarian function during use of a levonorgestrel-releasing IUD.
    Barbosa I; Bakos O; Olsson SE; Odlind V; Johansson ED
    Contraception; 1990 Jul; 42(1):51-66. PubMed ID: 2117516
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls.
    Bahamondes L; Brache V; Meirik O; Ali M; Habib N; Landoulsi S;
    Hum Reprod; 2015 Nov; 30(11):2527-38. PubMed ID: 26409014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hormonally impregnated intrauterine systems (IUSs) versus other forms of reversible contraceptives as effective methods of preventing pregnancy.
    French R; Van Vliet H; Cowan F; Mansour D; Morris S; Hughes D; Robinson A; Proctor T; Summerbell C; Logan S; Helmerhorst F; Guillebaud J
    Cochrane Database Syst Rev; 2004; 2004(3):CD001776. PubMed ID: 15266453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical performance of a levonorgestrel-releasing intracervical contraceptive device during the first year of use.
    Ratsula K
    Contraception; 1987 Dec; 36(6):659-66. PubMed ID: 3128429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protective effect of intrauterine release of levonorgestrel on pelvic infection: three years' comparative experience of levonorgestrel- and copper-releasing intrauterine devices.
    Toivonen J; Luukkainen T; Allonen H
    Obstet Gynecol; 1991 Feb; 77(2):261-4. PubMed ID: 1899136
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New developments in intrauterine devices.
    Farr G
    Netw Res Triangle Park N C; 1991 Sep; 12(2):9. PubMed ID: 12284281
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Levonorgestrel IUD].
    Skajaa K; Forman A
    Ugeskr Laeger; 1994 Nov; 156(46):6884-7. PubMed ID: 7839510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hormonally impregnated intrauterine systems (IUSs), versus other forms of reversible contraceptives as effective methods of preventing pregnancy.
    French R; Cowan F; Mansour D; Morris S; Hughes D; Robinson A; Proctor T; Summerbell C; Logan S; Guillebaud J
    Cochrane Database Syst Rev; 2001; (2):CD001776. PubMed ID: 11406007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The incidence of actinomyces-like organisms in Papanicolaou-stained smears of copper- and levonorgestrel-releasing intrauterine devices.
    Merki-Feld GS; Lebeda E; Hogg B; Keller PJ
    Contraception; 2000 Jun; 61(6):365-8. PubMed ID: 10958879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endometrial morphological changes in IUD users: a review.
    Sheppard BL
    Contraception; 1987 Jul; 36(1):1-10. PubMed ID: 3117492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intrauterine devices: an effective alternative to oral hormonal contraception.
    Prescrire Int; 2009 Jun; 18(101):125-30. PubMed ID: 19637436
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy in parous women of a 52-mg levonorgestrel-medicated intrauterine device: a 7-year randomized comparative study with the TCu380A.
    Rowe P; Farley T; Peregoudov A; Piaggio G; Boccard S; Landoulsi S; Meirik O;
    Contraception; 2016 Jun; 93(6):498-506. PubMed ID: 26916172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of the levonorgestrel intrauterine device in the prevention and treatment of iron deficiency anemia during fertility regulation.
    Faundes A; Alvarez F; Brache V; Tejada AS
    Int J Gynaecol Obstet; 1988 Jun; 26(3):429-33. PubMed ID: 2900174
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized clinical trial of the effect of intensive versus non-intensive counselling on discontinuation rates due to bleeding disturbances of three long-acting reversible contraceptives.
    Modesto W; Bahamondes MV; Bahamondes L
    Hum Reprod; 2014 Jul; 29(7):1393-9. PubMed ID: 24812309
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A morphometric study on the endometrial activity of women before and after one year with LNG-IUD in situ.
    Gu Z; Zhu P; Luo H; Zhu X; Zhang G; Wu S
    Contraception; 1995 Jul; 52(1):57-61. PubMed ID: 8521716
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acceptability of IUDs is increasing.
    Finger WR; Barr D
    Netw Res Triangle Park N C; 1992 Oct; 13(2):27-30. PubMed ID: 12286082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.